Researchers have discovered a novel way to empower mesenchymal stem cells (MSCs) to better control the inflammatory response in severe COVID-19 cases. By licensing MSCs with IFN-γ, a key immune signaling molecule, these cells can dramatically reduce the deadly “cytokine storm” that often leads to organ failure in COVID-19 patients. This promising approach could help save lives by preventing the lymphopenia (low white blood cell count) and immune dysfunction seen in critical COVID-19 cases.
Harnessing the Power of Stem Cells against COVID-19
The COVID-19 pandemic has devastated communities worldwide, with severe cases often leading to a dangerous immune overreaction known as the “cytokine storm.” In this condition, the body produces an excessive amount of inflammatory molecules, causing widespread tissue damage and organ failure. Finding ways to calm this deadly storm has become a critical priority for researchers.
One promising approach involves the use of mesenchymal stem cells (MSCs). These versatile cells, which can be derived from various tissues like adipose (fat) and bone marrow, have shown promising results in clinical trials for treating severe COVID-19. MSCs possess remarkable abilities to modulate the immune system and promote tissue repair, making them an attractive candidate for COVID-19 management.
Supercharging MSCs with IFN-γ
In a recent study, researchers from the University of Brasília in Brazil explored a novel strategy to enhance the therapeutic potential of MSCs against the SARS-CoV-2 virus. They discovered that licensing MSCs with the immune signaling molecule IFN-γ significantly boosts their ability to control the inflammatory response triggered by the virus.
The researchers first tested the effect of IFN-γ licensing on the immunomodulatory profile of MSCs. They found that this process increased the cells’ expression of key anti-inflammatory factors, such as IDO, PD-L1, and TSG-6. Importantly, IFN-γ licensing also reduced the expression of the TMPRSS2 enzyme, which the SARS-CoV-2 virus uses to enter host cells, suggesting these MSCs may be more resistant to viral infection.
Calming the Cytokine Storm
Next, the researchers established an in vitro model of the inflammation seen in severe COVID-19 by exposing lung cells to SARS-CoV-2 proteins. They found that this inflammatory environment severely compromised the viability of the lung cells and triggered the production of various inflammatory mediators, such as ICAM-1, CXCL10, and IFN-β.
Remarkably, when the researchers exposed T cells (a key player in the immune response) to this inflamed environment and then treated them with the IFN-γ-licensed MSCs, they observed a dramatic reduction in the levels of critical inflammatory cytokines like IL-6 and IL-10. Moreover, the IFN-γ-licensed MSCs were able to significantly inhibit T cell apoptosis (programmed cell death) induced by the SARS-CoV-2 proteins.
Preventing Immune System Collapse
The researchers’ findings suggest that IFN-γ-licensed MSCs could be a powerful tool in the fight against severe COVID-19. By reducing the levels of key inflammatory cytokines and protecting T cells from virus-induced apoptosis, these supercharged stem cells could help prevent the lymphopenia (low white blood cell count) and immune dysfunction that often lead to multiple organ failure in critical COVID-19 cases.
With further research and clinical trials, this innovative approach could pave the way for a new generation of stem cell-based therapies to manage the devastating effects of COVID-19. By harnessing the immune-modulating and tissue-regenerative abilities of MSCs, scientists may be able to turn the tide against the deadly cytokine storm and save lives.
Author credit: This article is based on research by Elizabete Cristina Iseke Bispo, Enrique Roberto Argañaraz, Franscisco de Assis Rocha Neves, Juliana Lott de Carvalho, Felipe Saldanha-Araujo.
For More Related Articles Click Here
